Adjunct to diet & exercise to improve glycaemic control in patients w/ type 2 DM as monotherapy or in combination w/ metformin, sulfonylurea, thiazolidinedione, when diet & exercise do not result in adequate glycemic control; on combination w/ sulfonylurea & metformin when diet & exercise plus dual therapy w/ these agents do not provide adequate glycemic control. Initial combination therapy w/ metformin in patients w/ type 2 DM whose diabetes is not adequately controlled by diet & exercise alone.
Dosage/Direction for Use
Monotherapy or in dual combination w/ metformin or thiazolidinedione or insulin (w/ or w/o metformin): 50 mg once daily in the morning or bid (morning & evening). Triple combination w/ sulfonylurea & metformin: 50 mg bid. In combination w/ sulfonylurea: 50 mg once daily. Moderate or severe renal impairment, or ESRD 50 mg daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Do not use in patients w/ type 1 DM or in treatment of diabetic ketoacidosis. Galactose intolerance, Lapp lactase deficiency malabsorption. Hepatic impairment. ALT or AST >2.5 x ULN. ESRD. Pregnancy & lactation. Childn <18 yr.
May result in glucose regulation w/ somastatin. Increased risk of hypoglycemia w/ thioctic acid. May result in changes in blood glucose & increased risk of hypoglycemia or hyperglycemia w/ fluoroquinolone. May result in hypoglycemia or hyperglycemia, or decreased symptoms of hypoglycemia w/ β-adrenergic blockers.
Sign Out
